Kalaris Therapeutics (KLRS) director receives stock options on 9,000 shares
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Kalaris Therapeutics director Jovan-Embiricos Morana received a stock option grant covering 9,000 shares of common stock. The option has an exercise price of $4.7200 per share and expires on June 2, 2036. The 9,000 underlying shares are scheduled to vest in full on the earlier of June 3, 2027 or the company’s 2027 annual stockholders’ meeting, subject to continued service. Following this grant, Morana holds options to purchase 9,000 shares directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Jovan-Embiricos Morana
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 9,000 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 9,000 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Option grant size: 9,000 shares
Exercise price: $4.7200 per share
Expiration date: June 2, 2036
+2 more
5 metrics
Option grant size
9,000 shares
Stock Option (Right to Buy) granted to director
Exercise price
$4.7200 per share
Exercise price for 9,000-share option grant
Expiration date
June 2, 2036
Option term end date
Post-grant option holdings
9,000 shares
Total options held directly after transaction
Vesting date trigger
June 3, 2027
Earlier of this date or 2027 annual meeting
Key Terms
Stock Option (Right to Buy), exercise price, vest in full, expiration date
4 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 4.7200"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vest in full financial
"shares underlying the option are scheduled to vest in full"
expiration date financial
"expiration_date: 2036-06-02T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
What did Kalaris Therapeutics (KLRS) disclose in this Form 4?
Kalaris Therapeutics reported a stock option grant to director Jovan-Embiricos Morana for 9,000 shares. The option has an exercise price of $4.7200 per share and represents compensation rather than an open-market stock purchase or sale.
What is the exercise price and expiration date of the KLRS option grant?
The stock option granted to the director has an exercise price of $4.7200 per share and expires on June 2, 2036. These terms define the cost to acquire shares and the final date by which the option must be exercised.
When do the KLRS stock options granted to the director vest?
The 9,000 shares underlying the option are scheduled to vest in full on the earlier of June 3, 2027 or the date of Kalaris Therapeutics’ 2027 annual stockholders’ meeting. Vesting is conditioned on the director’s continued service with the company.
How many KLRS options does the director hold after this transaction?
After this transaction, the director holds stock options to purchase 9,000 shares of Kalaris Therapeutics common stock directly. This reflects the total derivative holdings reported in connection with this grant in the Form 4 filing.